Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To evaluate the potential usefulness of 68Ga/18F-PSMA/PSFA positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients (prostate cancer, hepatic cancer, etc.).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Podejrzenie nowotworu lub niedawna diagnoza lub wcześniejsze leczenie raka
- •Zaplanowane badanie PET/CT z użyciem znacznika PSMA
- •Możliwość udzielenia pisemnej zgody na udział w badaniu
✗ Disqualifies
- •Niełośliwe zmiany (nie będące rakiem)
- •Ciąża
- •Brak możliwości lub chęci do podpisania zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- September 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
The Affiliated Hospital of Qingdao University
Qingdao, China
Tianjin Medical University General Hospital
Tianjin, China
Trial contact
Haonan Yu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.